Incyte announced four rapid oral presentations at ESMO Congress 2026 for its KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890, both in Phase 3. An investor webcast is scheduled for Oct 26.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
